|
|
|
| home > ebr > Summer 2011 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
IP Strategies
License to Thrill
In the increasingly competitive world of biotechnology, a robust R&D plan needs to have an equally strong IP strategy in place to succeed. With this in mind, Haydn Evans of CPA Global explains the importance of in-licensing.
|
|
|
Drug Repositioning: Small Biotech
An Alternative Path to Drug Discovery
Núria Gavaldà, Núria Reig and Marc Centellas of SOM BIOTECH draw comparisons between multiple drug repurposing case studies, while evaluating the technology platforms and partnering opportunities that could potentially aid these strategies.
|
|
|
Early Stage Drug Discovery
Behind the Screens
Early stage screening offers an affordable way to minimise the possibility of late stage failures. Sandhya Vellore of GBI Research looks at the technologies available for screening potential molecules as well as the latest trends in this market.
|
|
|
|
Adult Stem Cells
Life and Limb
Bone marrow has been shown to not only be the origin of blood cells, but other types of cells that participate in tissue remodelling and angiogenesis. Ronnda L Bartel, Sharon Watling and Eric Kaldjian at Aastrom Biosciences focus on how bone marrow-derived therapies are being adapted for the lab.
|
|
|
Vaccine Innovation
Implementing Immunostimulants
Frédéric Durmont and Maxence de Villemeur of Lallemand Pharma discuss polyvalent chemical and mechanical bacterial lysates to show how their application affects the oral vaccines market.
|
|
|
|
|
Industry Insight: Cell Therapeutics
Finding the Right Place
More sophisticated tools for molecular characterisation and the ability to link this back to the biology involved will be instrumental in delivering full characterisation of the cell, the process and consequently the product, reports Verna McErlane of Sistemic.
|
|
|
|
|
Therapeutic Antibodies
Novel Libraries
Markus Enzelberger of MorphoSys discusses the impact combinatorial antibody libraries have had on drug discovery and development, and makes predictions about where this technology is going
|
|
|
|
|
System Control: Data Analysis
Tools of the Trade
Carl-Johan Ivarsson of Qlucore looks at how tools such as principal component analysis and heat maps have provided a powerful way of identifying important structures and patterns, allowing for better comparison of data.
|
|
|
First-in-Man Clinical Trials
Best Laid Plans
Paul Titley of Aesica, R5 Formulation Development offers tips on reducing the cost of expensive first-time-in-man trials, focusing on the management and evaluation techniques that can help to avoid future wastage.
|
|
|
|
Non-Clinical Safety Testing
Species Selection
In order to test the safety of new therapeutic mAbs, non-clinical studies have to be carried out using pharmacologically relevant species. Lolke de Haan, Simon Henderson,Mary McFarlane, Alison Scott and Jacintha Shenton of MedImmune analyse the factors involved in determining a species’ relevance to a study.
|
|
|
Assessing Biosimilars
Spot the Difference
With specific reference to international regulations for categorising biosimilars, Shein-Chung Chow of Duke University School of Medicine discusses the fundamentals of biosimilarity and interchangeability.
|
|
|
|
Phage Production
The Age of Phage
Despite a relative lack of interest in phage biology in the past, researchers are now tapping into the potential of this niche research area.Marcin Los of Phage Consultants considers what we can expect to see from biophages in the future.
|
|
|
Therapeutic Proteins in Plants
Turning a New Leaf
The field of plant-made pharmaceutical therapeutics is hitting a critical point as developers begin looking for regulatory approval. Qiang Shawn Chen of Arizona State University suggests how the future production of biobetters and biosimilars is set to change under the increasing pressure of public perceptions of environmental risk.
|
|
|
Liquid Handling Techniques
Fluid Thinking
Joby Jenkins of TTP LabTech runs a cost:benefit assessment of various liquid handling technologies and runs through methods of minimising the cost of screening through higher throughputs, miniaturising assay formats and streamlining the assay process.
|
|
|
|
Q&A: Industry Advisors
Biopharm: Past, Present and Future
EBR’s new Industry Advisory Board give their opinions on the current shape of the biotechnology market and how they anticipate it changing in the years to come.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
New awareness campaign aims to help organisations prepare for GS1
More info >> |
|
 |
White Papers |
 |
|
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Perceptive Informatics
Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >> |
|
 |
Industry Events |
 |
Outsourcing in Clinical Trials Medical Devices 2017
27-28 June 2017, Santa Clara, CA
OCT Medical Devices moved to Irvine, California for the first year in 2016, and we are pleased to say it proved a resounding success. As the only event to cater for the Southern California Medical device hub in Irvine, it brought together a variety of medical device companies of all sizes, including Medtronic, Edwards Lifesciences, Onciomed, Inc and St Jude Medical.
More info >> |
|
|
